Shandong Sinobioway
Weiming Biomedical Pharmaceutical Co., Ltd. is a Fujian Province-based biopharmaceutical company and core enterprise of the Beijing University Weiming Group, commercializing nerve growth factor and related therapeutics to Chinese medical institutions and nerve damage patients via a sales-led distribution model.
- Company typePrivate
- Founded1998
- HeadquartersXiamen, China
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
Shandong Sinobioway firmographics
Firmographics- Name
- Shandong Sinobioway
- Legal name
- 未名生物医药有限公司
- Website
- https://bioway-pku.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Weiming Biomedical Pharmaceutical Co., Ltd. is a Fujian Province-based biopharmaceutical company and core enterprise of the Beijing University Weiming Group, commercializing nerve growth factor and related therapeutics to Chinese medical institutions and nerve damage patients via a sales-led distribution model.
- Ownership category
- akta.pro rank
Shandong Sinobioway industry classification
Industry- Product category
- Biopharmaceutical Products
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)
Keywords
Where Shandong Sinobioway is headquartered
LocationHeadquarters
- HQ city
- Xiamen
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
Shandong Sinobioway business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Supply Chain, Personnel, Marketing or Sales
Revenue model
- Biopharmaceutical Product Sales: Revenue generated from the sale of biopharmaceutical products including nerve growth factor medications, interferon products, and other therapeutic drugs to medical institutions and patients.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Shandong Sinobioway product offering
Product offeringCore offering
Shandong Sinobioway is a Chinese biopharmaceutical enterprise that develops, manufactures, and commercializes therapeutic biological drugs, with core products including the mouse nerve growth factor injection 恩经复 (Enjingfu), along with 安福隆 (Anfulong) and 捷抚 (Jiefu). The company is the core biopharmaceutical subsidiary under the Beijing University Weiming Group (北大未名集团), and its flagship 恩经复 is recognized as the only Nobel Prize-winning physiological medicine industrialized by Chinese scientists, used to treat nerve damage and promote motor and sensory function recovery.
Differentiator
Problem solved
Functional benefit
Products and services
- 恩经复 (Enjingfu) — Mouse Nerve Growth Factor Injection (注射用鼠神经生长因子) A Nobel Prize-winning physiological medicine industrialized by Chinese scientists, used as a nerve damage treatment drug acting through a direct action mechanism to promote recovery of motor and sensory function; prescribed by physicians in hospitals and clinical settings for patients with nerve injury.
- 安福隆 (Anfulong) A biopharmaceutical product in Shandong Sinobioway's portfolio, manufactured and commercialized by the company for therapeutic use.
- 捷抚 (Jiefu) A biopharmaceutical product in Shandong Sinobioway's portfolio, manufactured and commercialized by the company for therapeutic use.
Companies that use Shandong Sinobioway
Customer profileSegments1 record
Ideal customer profiles1 record
Shandong Sinobioway technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Shandong Sinobioway partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- Peking University (北京大学)coreStrategic partnership established in December 1998 between Peking University and Xiamen City Government in the field of biomedical technology. This collaboration represents a landmark university-government partnership in China's biomedical sector, serving as the foundation for the company's establishment as a crystallization of Beijing University and Xiamen's cooperation in biomedical science and technology.
- Xiamen City Government (厦门市)corePartnership with Xiamen City Government for biomedical technology development, representing a key regional government-university collaboration initiative in the biopharmaceutical sector.
- Beijing University Weiming Group (北大未名集团)coreCore enterprise within the Beijing University Weiming Group's biopharmaceutical sector. The company is a key subsidiary and strategic core asset of the group, representing its main biopharmaceutical business platform.
- European Brain Research Institute (欧洲脑研究所)majorJoint establishment of a China laboratory with the European Brain Research Institute, representing international scientific collaboration in neuroscience research and brain-related drug development. This partnership provides access to European research expertise and international scientific collaboration in neurotrophic factor research.
Scale indicators3 records
Shandong Sinobioway competitors and assessment
Company assessmentMarket position
Customer concentration
Shandong Sinobioway compliance and trust
Trust signalCompliance2 records
Shandong Sinobioway financial estimates
Financial estimateRevenue estimate
Valuation estimate
Shandong Sinobioway leadership team
Management profileNumber of profiles
Shandong Sinobioway funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Shandong Sinobioway M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Shandong Sinobioway
What does Shandong Sinobioway do?
Shandong Sinobioway is a Chinese biopharmaceutical enterprise that develops, manufactures, and commercializes therapeutic biological drugs, with core products including the mouse nerve growth factor injection 恩经复 (Enjingfu), along with 安福隆 (Anfulong) and 捷抚 (Jiefu). The company is the core biopharmaceutical subsidiary under the Beijing University Weiming Group (北大未名集团), and its flagship 恩经复 is recognized as the only Nobel Prize-winning physiological medicine industrialized by Chinese scientists, used to treat nerve damage and promote motor and sensory function recovery.
Is Shandong Sinobioway a public or private company?
Shandong Sinobioway is a private company. It is classified as corporate owned and is currently operating.
When was Shandong Sinobioway founded?
Shandong Sinobioway was founded in 1998. It employs 251 to 500 people.
Where is Shandong Sinobioway based?
Shandong Sinobioway is headquartered in Xiamen, China, in the Asia region.
How does Shandong Sinobioway make money?
One revenue line is on record: biopharmaceutical Product Sales.
Does Shandong Sinobioway have an API?
No public API is recorded for Shandong Sinobioway.
What industry is Shandong Sinobioway in?
Shandong Sinobioway's product category is Biopharmaceutical Products. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives. Its NAICS code is 325414 and its SIC code is 2836.